Article Versions Notes

Chen Y, Qiu X, Wu D, Lu X, Li G, Tang Y, Jia C, Xiong Z, Wang T. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. Genes. 2022; 13(9):1535. https://doi.org/10.3390/genes13091535

Chen, Yinkui, Xiusheng Qiu, Donghao Wu, Xu Lu, Guanghui Li, Yongsheng Tang, Changchang Jia, Zhiyong Xiong, and Tiantian Wang. 2022. "PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma" Genes 13, no. 9: 1535. https://doi.org/10.3390/genes13091535

Chen, Y., Qiu, X., Wu, D., Lu, X., Li, G., Tang, Y., Jia, C., Xiong, Z., & Wang, T. (2022). PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. Genes, 13(9), 1535. https://doi.org/10.3390/genes13091535